Clinical Trial Update: Adebrelimab Neoadjuvant Treatment for Resectable ESCC [NA]

View source ↗

Summary

The document reports a clinical trial evaluating adebrelimab as neoadjuvant therapy for resectable esophageal squamous cell carcinoma, with recruitment not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: ESCC | NA | Status: NOT_YET_RECRUITING